Page 30 - Astrazeneca

When will India finally have access to coronavirus vaccine?

India commands 40 per cent of global capacity for vaccines which is estimated at 5.7 billion doses

Covid updates: Job loss in India, Australia's 'vaccine must' policy, & more

Maharashtra has more than 600,000 confirmed coronavirus cases, which is almost equivalent to the case tally of the next two worst-affected states - Tamil Nadu and Andhra Pradesh - put together

Australia to give free Covid vaccine doses to citizens: PM Scott Morrison

Prime Minister Scott Morrison said Australia had reached a deal with Swedish-British pharmaceutical company AstraZeneca to receive the Covid-19 vaccine it is developing with Oxford University

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

Expects to complete trials by year-end

Blow to WHO? EU clinches first Covid-19 vaccine deal with AstraZeneca

The EU move could complicate efforts led by the WHO and GAVI, a global alliance for vaccines, to buy shots on behalf of rich and developing countries with a separate scheme

European Union, AstraZeneca agree bloc's first Covid-19 vaccine deal

The European Commission said on Friday it had reached a deal with British pharmaceutical firm AstraZeneca for the purchase of at least 300 million doses of its potential COVID-19 vaccine.

AstraZeneca says could begin Covid-19 vaccine production early in 2021

AstraZeneca Mexico's head said that Phase III trials were expected to conclude by November or December

US inks $1.5 bn deal with Moderna for 100 mn doses of Covid-19 'vaccine'

The US government previously gave Moderna around $1 billion to fund its research efforts, bringing total US funding to around $2.5 billion

AstraZeneca Pharma India Q1 net profit declines 13 pc at Rs 18.63 cr

Drug firm AstraZeneca Pharma India on Monday reported a 13.38 per centdecline in its net profit to Rs 18.63 crore for the quarter ended June. The company had posted a net profit of Rs 21.51 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a BSE filing. Revenue from operations stood at Rs 193.57 crore for the quarter under consideration. It was Rs 204.56 crore for the same periodyear ago, it added. The board of directors has declared an interim dividend of Rs 2 per equity share for the financial year 2020-21, the filing said. Shares ofAstraZeneca Pharma India were trading at Rs3,381.65per scrip on BSE, up 1.50 per cent over previous close.

AstraZeneca in deal with Kangtai Bio to supply Covid-19 vaccine in China

AstraZeneca signed an exclusive framework agreement with China's Shenzhen Kangtai Biological Products to supply its Covid-19 vaccine candidate in mainland China

Rich nations rush to lock up Covid vaccines: What about rest of the world?

Moves by the US and UK to secure supplies from Sanofi and partner GlaxoSmithKline Plc, and another pact between Japan and Pfizer Inc., are the latest in a string of agreements

AstraZeneca betters estimates amid strong sales, Covid-19 vaccine hopes

The company reiterated that it was on track with late-stage trials for its coronavirus vaccine, which could be rolled out by the year-end

AstraZeneca's drug gets US FDA nod to treat lung disease patients

The drug Breztri Aerosphere is being approved as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD), the third leading cause of death globally

AstraZeneca agrees to pay Japan's Daiichi $6 bn for new cancer drug

The UK drugmaker will pay Japan's Daiichi $1 billion upfront to jointly develop and bring to market a cancer therapy in early clinical tests called DS-1062, the companies said

More than enough doses of Covid-19 vaccine reserved for Parsis: Poonawalla

Serum Institute CEO didn't specify quantity of doses to be kept for community grappling with shrinking population

Adar Poonawalla: A rare risk-taking CEO with strong business acumen

Adar Poonawalla's Serum Institute has tied up with AstraZeneca-backed Oxford vaccine candidate for one billion doses which it will make for India and the GAVI vaccine alliance of 58 countries

Govt to ensure regulatory facilitation for Serum's Covid-19 vaccine trials

Serum Institute of India, the largest vaccine manufacturer in the world, has been chosen by Oxford and its partner AstraZeneca to manufacture the vaccine once it gets ready.

We want to price Covid-19 vaccine below Rs 1,000: Serum Institute CEO

Pune's Serum Institute of India is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222

Oxford-Astra Covid-19 vaccine shows dual immune action, says researcher

Study shows the vaccine is safe, but it is still too soon to know if it can stop people from being infected

Covid-19 vaccine: Oxford candidate safe, shows immune response in trial

The preliminary results of the phase 1-2 trial, published in The Lancet journal, involved 1,107 healthy adults, and found that the vaccine induced an immune response both via antibodies and T-cells